PRESS RELEASE FOR NATURE BIOTECHNOLOGY
(<http://www.nature.com/nbt/>)
This press release is copyrighted to Nature Biotechnology.
Warning: This document, and the Nature papers to which it refers, may contain information that is price sensitive (as legally defined, for example, in the UK Criminal Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in securities using information contained in this document or in advanced copies of Nature’s content may be guilty of insider trading under the US Securities Exchange Act of 1934.
PLEASE CITE Nature BIOTECHNOLOGY AND THE Nature BIOTECHNOLOGY WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO www.nature.com/nbt <http://www.nature.com/nbt>
Insulin-producing cells from human embryonic stem cells
DOI: 10.1038/nbt1259
The culture conditions under which human embryonic stem cells can be converted into cells that produce all five hormones made by the pancreas, including insulin, are reported online in Nature Biotechnology this week. Baetge and colleagues’ study suggests that the possibility of turning human embryonic stem cells into pancreatic cells that can be used for diabetes therapy has moved one step closer to reality.
Human embryonic stem cells have the potential to become virtually any cell type in the body. Thus, they are a promising source of cells to repair damaged organs like the pancreas, heart and liver. The challenge facing scientists is to unlock the secrets of how to produce particular cell types, such as pancreatic beta-cells - the insulin-secreting cells in the pancreas - with high efficiency.
Baetge and colleagues show that the efficient generation of insulin-producing cells from human embryonic stem cells depends on guiding the cells through stages similar to those of pancreatic development, including the critical early developmental stage known as ‘definitive endoderm.’ The insulin-producing cells the authors created contained high levels of insulin. They were also capable of secreting insulin, but only minimally in response to sugar - a crucial function of adult beta-cells. Thus, the cells seem closer to immature, fetal beta-cells. The authors speculate that, with additional research, these cells have the potential to be matured into insulin-producing cells that could be suitable for transplantation into patients.
Author contact:
E Edward Baetge (Novocell Inc., San Diego, CA, USA)
Tel: +1 858 455 3555; E-mail: [email protected]
PRESS CONTACTS…
Ruth Francis, Nature London
Tel: +44 20 7843 4562; E-mail [email protected]
Helen Jamison, Nature London
Tel: +44 20 7843 4658; E-mail: [email protected]
For media inquiries relating to editorial content/policy for Nature Biotechnology, please contact the journal directly:
Gaspar Taroncher-Oldenburg, Nature Biotechnology
Tel: +1 212 726 9364; E-mail: [email protected]
About Nature Publishing Group
Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd, dedicated to serving the academic, professional scientific and medical communities. NPG's flagship title, Nature, was first published in 1869. Other publications include Nature research journals, Nature Reviews, Nature Clinical Practice and a range of prestigious academic journals including society-owned publications. NPG also provides news content through [email protected] and scientific career information through Naturejobs.
NPG is a global company with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Munich, Hong Kong, Melbourne, Delhi, Mexico City and Basingstoke. For more information, please go to <www.nature.com>.
